Ligands of the FSH hormone receptor in the diagnosis and treatment of tumors
Patent Information
- Application Number
- IN201917016692
- Authority / Receiving Office
- IN · IN
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-10-11
- Filing Date
- 2019-04-26
- Publication Date
- 2026-10-08
- Estimated Expiration
- 2037-10-10
AI Technical Summary
Current methods for developing FSHR-specific ligands, such as synthetic peptides and monoclonal antibodies, face limitations in specificity and stability, and there is a need for alternative approaches to diagnose and treat cancers involving the FSH receptor effectively.
The β subunit of the human follicle stimulating hormone (FSH) is found to bind with high affinity to FSHR and can be produced in a stable form using recombinant DNA technology, allowing for the development of pharmaceutical preparations that can be used for cancer treatment and diagnosis by conjugating with therapeutic or diagnostic molecules.
The recombinant β subunit of FSH, particularly the ABRβI form, demonstrates high affinity binding to FSHR, providing advantages in cancer treatment and diagnosis, including receptor inactivation and imaging capabilities, with potential for use in various types of tumors and pediatric neuroblastoma.
Abstract
Description
The follicle stimulating hormone (FSH) is a glycoprotein belonging to the class of glycoprotein hormones (GPHs), which includes proteins characterized by a high structural similarity, such as the thyroid-stimulating hormone (TSH) , the luteinizing hormone (LH) and chorionic gonadotropin (CG) .FSH is synthesized in the anterior pituitary gland and released into the bloodstream as a result of the gonadotropin-releasing hormone (GnRH) stimulation.FSH plays a key role in the physiology of reproduction, inducing maturation of the ovarian follicle in women, while in men it stimulates the Sertoli cells promoting spermatogenesis (Simoni et al . 1997) .Recombinant FSH-based preparations, such as Puregon® and Gonal-F®, or of extraction from urine, such as Fostimon®, are routinely used in clinical practice to treat infertility in both women and men and in assistedlprocreation protocols (Barroso et al. 2013).FSH is a heterodimer composed of two non-covalently associated subunits, a and β.The a subunit is common to all GPHs, while the β subunit varies in different glycoprotein hormones and defines their specific biological activity.The β subunit (UniProt code: P01225) of the human follicle stimulating hormone (ΓΞΗβ) has a molecular weight of about 12.5 kDa and consists of 111 amino acid residues of which 12 cysteine residues, involved in the formation of 6 disulfide bridges. There are two N-glycosylation sites in the protein at the level of the asparagine 7 and asparagine 24 residues.The bioactivity of the FSH hormone depends on the glycosylation state of the asparagine 52 residue of the a chain which plays an important role in inducing the biological response.Moreover, the glycosylation pattern at the ΓΞΗβ level influences the hormone binding capacity to the specific receptor .Hypoglycosylated forms are provided with greater affinity for the receptor in vitro but shorter half-life times in vivo, whereas the opposite phenomenon is observed for the isoforms characterized by a complete glycosylation (Ulloa-Aguirre et al . 2011) .FSH, released in the bloodstream, is capable of reaching any district of the organism through microcirculation. FSH exerts its physiologic action through binding and activation of a specific receptor (FSH Receptor, FSHR) .Under physiological conditions, the receptor is expressed in men only in the Sertoli cells of the testes, and only in granulosa ovarian cells in women.The FSH receptor belongs to the family of G-protein coupled receptors and the formation of the ligand-receptor complex triggers a series of cascade signals whose metabolic significance is not completely known.The most studied physiological effect is the activation of the adenylyl cyclase enzyme which converts adenosine monophosphate (AMP) in the second messenger cyclic adenosine-monophosphate (cAMP) , increasing its cytosolic concentration.cAMP is a strong activator of the protein kinase A (PKA) which represents a key enzyme in the regulation of different processes essential to the life of the cell.In the Sertoli cells, for example, the activation of the FSHR results in the increase of the expression of aromatase, an enzyme which converts testosterone to 17β-estradiol, stimulating the metabolic processes associated with it (Ulloa-Aguirre et al . 1998) .Already in the years 1999-2000, the scientific community began to highlight the abnormal expression of FSHR in prostate cancers but above all in ovary cancers (Ben-Josef et al . 1999; Zheng et al . 2000) .In later years, evidence to that effect increased significantly, but only in 2010 Radu and colleagues (Radu et al . 2010) demonstrated that FSHR is expressed in an abnormal manner at the level of the microcirculation endothelial tissues of many solid tumors.Later, the evidence that in ovarian tumors, the over-expression of FSHR is correlated with the severity of the disease was consolidated; several evidences were also produced which confirmed Radu' s work (Radu et al . 2010) and demonstrated that FSHR is expressed at high levels in different types of primary or metastatic solid tumors (Pawlikowski et al . 2015; Planeix et al . 2015; Siraj et al. 2013; Sardella et al . 2012; Siraj et al . 2010) .FSHR ligands being developedAt present, research for FSHR specific ligands follows two main methodologies: i) the development of synthetic peptides, ii) the development of monoclonal antibodies.Both strategies have significant drawbacks such as limited specificity in the case of peptides, or inherent instability in the case of antibodies.The molecule with the highest binding specificity for FSHR known to date is FSH, physiologically present in nanomolar (nM) concentration in the bloodstream.It is therefore necessary to identify new and valid alternatives to existing ones, which allow to specifically reach, diagnose and treat cancers involving the FSH receptor .The prior art document Luo S. et al . (European Journal of nuclear medicine and molecular imaging, vol. 40, no. 2, 16 October 2013) describes an ΡΞΗβ subunit peptide for the diagnosis of prostate cancer. It does not describe applications for neuroblastoma.The publication of Zhang Xiaoyan et al . (International Journal of Pharmaceutics, vol. 453, no. 2, 2013) describes the conjugation of an FSR subunit peptide with paclitaxel in the treatment of cancer.The European patent application EP 2,090,322 Al (Inst. Nat. Rech. Med.) describes a ligand of the FSHR for the imaging and the treatment of tumors which can be represented by FSH. As is known, FSH comprises two subunits (a and β) .The European patent application EP 2,924,049 Al describes the use of chimeric gonadotropins in the treatment of trophic hormone-related diseases.The international patent application WO 2014 / 078533 Al describes fusion constructs comprising fragments of the ΓΞΗβ subunit or the ΓΞΗβ subunit bound to a lithic domain. It does not show any evidence in the use for the treatment of neuroblastoma.The international patent application WO 2016 / 054153 Al describes a gene construct comprising a fragment of FSH or the FSYl subunit.The publication of Zhang et al (Cancer Research, vol. 69, no. 16, 15 August 2009) describes the conjugation of paclitaxel with a fragment of the ΓΞΗβ subunit in the treatment of cancer.Summary of the inventionThe present invention is based on having surprisingly found that the β subunit of the human follicle stimulating hormone (ΓΞΗβ) is capable of binding to FSHR with high affinity.In particular, it has been found that the β subunit of the human follicle stimulating hormone (ΓΞΗβ) can inactivate FSHR.In addition, the inventors of the present patent application have found that forms of the ΓΞΗβ subunit obtained by employing the recombinant DNA technology can also be produced in a highly stable form.These forms have shown to bind with high affinity to FSHR allowing special and surprising advantages.Object of the inventionA first object of the present invention is represented by the medical use of the human follicle stimulating hormone β (ΓΞΗβ) subunit.According to particular aspects, the human follicle stimulating hormone β (ΓΞΗβ) subunit finds application for medical use in the treatment and / or diagnosis of tumors .In a second object thereof, the invention describes a biotechnological platform for the preparation of the β subunit of the human follicle stimulating hormone in recombinant form (ΑΒΚβ) .The β subunits of the human follicle stimulating hormone (ΑΒΚβ) obtained with such a platform are further objects of the present invention.The medical use of these subunits, and particularly the medical use in the treatment and / or diagnosis of cancer, are further objects of the present invention.According to another aspect, pharmaceutical preparations for administering the FSR and ΑΒΚβ subunits are described.In such preparations, said ΓΞΗβ and ΑΒΚβ subunits can be conjugated with molecules having therapeutic or diagnostic activity.The nucleotide sequences of the constructs and vectors used to obtain the described recombinant forms represent, each, further aspects of the present invention, as the novel amino acid sequences described.In another object thereof, the present invention describes a method for the treatment and / or diagnosis of cancer comprising the use of the ΓΞΗβ or ΑΒΚβ subunits.In a further object of the present invention, the use of the FSR or ΑΒΪβ subunits for the FSH (FSHR) receptor inactivation is described.According to a further aspect of the invention, a process is described herein for preparing a ligand of the human follicle stimulating hormone (ΑΒΚβ or ΑΒΚβΙ) receptor, comprising the preparation of a β subunit of the recombinant human follicle stimulating hormone (ΓΞΗβ) having a modification of the C-terminal region represented by the introduction of the KDEL sequence.In a particular aspect, such a process may further comprise the modification at the N-terminal end of the sequence of the β subunit of the human follicle stimulating hormone (ΓΞΗβ) represented by the introduction of a His-tag.Therefore, the use of the KDEL sequence at the C-terminal end and possibly the use of a His-tag at the N-terminal end of the sequence of the β subunit of the human follicle stimulating hormone (ΓΞΗβ) for preparing ligands of the human follicle stimulating hormone (ΓΞΗβ) receptor represent further objects of the present invention.Brief description of the figuresFigure 1 shows the structure of the binary vector pABR: RB / LB, specific recombination sites, left edge and right edge; Tml_p, promoter of the tumor morphologylarqe DNA; NPT II, neomycin phosphotransferase II; Tml_t, terminator of the tumor morphologylarqe DNA; CaMV35x2_p, promoter of the cauliflower mosalcvirus ; TEV 5', untranslated TEV sequence; Nos_t, terminator of the nopalyne synthase;Figure 2 shows the results of the electrophoretic analysis of purified ΑΒΚβΙ;Figure 3 shows the SDS-PAGE analysis after deglycosylation of purified ΑΒΚβΙ;Figure 4 shows the mass spectrum of purified ABRβl (band at 25kDa) ;Figure 5 shows the results of the analysis of the aggregation state of the ligand ABRβl throughsize exclusion chromatographyin HPLC;Figure 6 shows the results of the stability analysis of the ligand ABRβl by fluorimetric technique;Figure 7 shows the results of the analysis of the effect of ABRβl on the activation of FSHR through measurement of the production of estradiol (E2) in Sertoli cells. Data are represented as mean ± SD (n=3) . CTR: untreated cells; Gonal F: cells treated with the commercial drug; ΑΒΚβΙ: cells treated with the purified ligand ΑΒΚβΙ; T: cells supplemented with testosterone;Figure 8 shows the results of the analysis of the binding of ΑΒΚβΙ labeled with NBD to FSHR in cancer cells;Figure 9 shows the result of the analysis of the internalization of Gonal F (Panel A and B) and ΑΒΚβΙ (Panel C and D) in HeLa cells transformed with human FSHR. Cells incubated with FITC secondary antibody only (Panel A and C) ;Figure 10 shows the results of the cAMP production induced by Gonal F and neutralized by the ligand ΑΒΚβΙ;Figure 11 shows the effect of the ligand ABRβl on the growth of cancer cells;Figure 12 shows the effect of the ligand ABRβl labeled with Alexa Fluor 647 on the growth of cancer cells;Figure 13 shows the results of the analysis of internalization of the ligand ABRβl in cancer cells performed with flow cytometry technique;Figure 14 shows the location of the ligand ABRβl and its localization in the lysosomal compartment of cancer cells ;Figure 15 shows the result of the expression analysis of FSHR by immunoflow cytometry technique in a panel of human cancer cells;Figure 16 shows an example of boxplots obtained as the output from the FSHR gene expression data analysis conducted by querying the ArrayExpress (EMBL) database. The dataset analyzed includes 504 human infant neuroblastoma samples;Figure 17 shows the results of the analysis of the binding of ΑΒΪβΙ labeled with NBD to FSHR in NB3 cells;Figure 18 shows the results of the analysis of internalization of ΑΒΪβΙ labeled with NBD in NB3 cells (a fraction higher than 96% of treated cells shows the appearance of signal localized in cytoplasmic vesicles (panel B) (n=3) . Untreated cells (Panel A));Figure 19 shows the amino acid sequence coverage through mass spectrometry analysis of the deglycosylated form of the ligand ΑΒΚβΙ subjected to tryptic digestion (CAM: carbamido-methylcysteine; (1) : missed cleavage; MSO: methionine sulfoxide);Figure 20 shows the expression analysis of FSHR by immunoflow cytometry technique in human neuroblastoma cancer cells;Figure 21 shows the effect (over time) of the caudal vein injection of ΑΒΚβΙ in a mouse model.Detailed description of the inventionDefini tionsIn the present description of the invention, where not otherwise indicated, the terms shall be understood as having the meaning set forth hereinafter."FSHR" means the human follicle stimulating hormone (FSH) receptor; this hormone includes the two a and β subunits ."ΓΞΗβ" means the single beta subunit of the human follicle stimulating hormone (FSH); this subunit is characterized by the sequence corresponding to SEQ. ID. no . 1."ΑΒΚβ" means the beta subunits of the human follicle stimulating hormone (FSH) obtainable by using a biotechnological platform according to the present invention ."ΑΒΚβΙ" means a specific beta subunit of the human follicle stimulating hormone (FSH) obtained by using the biotechnological platform for the production in plant cells of Nicotiana benthamiana according to the present invention; this subunit is characterized by the amino acid sequence corresponding to SEQ. ID. no. 2.More generally, the FSR , ΑΒΪβ and ΑΒΪβΙ subunits may be referred to as "ligand" of the FSHR receptor as they are capable of binding to the receptor itself.According to a first object of the present invention, the medical use of the β subunit of the human follicle stimulating hormone (ΓΞΗβ) is described.In particular, the present invention describes the use of the β subunit of the human follicle stimulating hormone (ΓΞΗβ) in the treatment and / or diagnosis of cancer .The term cancer refers to tumor and cancer, i.e. those tissues characterized by an abnormal growth caused by an uncontrolled cellular multiplication.In a preferred aspect, such a tumor or cancer is a primary or metastatic solid tumor.In detail, prostate (in particular prostate adenocarcinoma) , mammary gland, colon, pancreas, kidney, lung, liver, testis, ovary, brain and thyroid tumors and cancers are included; sarcomas are also included.According to an aspect of the invention, such a medical use may find application in the treatment of infant neuroblastoma.In particular, such a medical use is described in pediatric patients and, preferably, in patients up to 6 years of age.For the purposes of the present invention, the ΓΞΗβ subunit is used in cancer therapy as such or combined with anticancer agents.In the form not conjugated to any drug, the ΓΞΗβ subunit may be used as an FSH competitor in the binding with FSHR and thus capable of blocking the activity of the receptor.As for the anticancer drugs which can be used and conjugated to the β subunits, these may belong to:- the class of cytotoxic agents. Preferably, such compounds are selected from the group comprising: pyrimidine antagonists, such as capecitabine, enzyme inhibitors, such as the camptothecins family, for example irinotecan;- the class of alkylating agents. Preferably, such compounds are selected from the group comprising: the metal salts family, such as cisplatin, DNA intercalators , such as doxorubicin, the anthracycline family;the class of protein synthesis modulators. Preferably, such compounds are selected from the group comprising: the proteasome inhibitors family, such as bortezomib, the mTOR inhibitors family, such as temsirolimus ;- the class of mitotic inhibitors.Preferably, such compounds are selected from the group comprising: the ansamitocin family, such as maytansine, the microtubule polymerization inhibitors family, such as auristatin E;- the class of β-emitting radioisotopes. Preferably, such compounds are selected from the group comprising: 131I, 169Er, 177Lu, 186Re, 153Sm, 89Sr and 90Y.According to an aspect of the invention, the FSt^ subunit is used in the diagnosis of tumors.In particular, they are the tumors and cancers mentioned above.Once suitably conjugated, the FSR subunit therefore allows the detection in diagnostic imaging in oncology.The techniques used to this end include, for example: Positron Emission Tomography (PET) , Nuclear Magnetic Resonance (NMR) , Single Photon Emission Tomography (SPECT) and ultrasound; therefore, the FSt^ subunit can be suitably conjugated with molecules suitable for diagnosis using techniques such as: Positron Emission Tomography (PET), Nuclear Magnetic Resonance (NMR), Single Photon Emission Tomography (SPECT) and ultrasound.For the present purposes, the term diagnosis also refers to the ability of checking the tumor progression over time and / or its progression or regression during a therapeutic treatment.For the purposes of the present invention, diagnosis also means using the FSt^ subunit to conduct in vitro analysis for laboratory purposes.According to a first aspect, the FSt^ subunit may be suitably conjugated with fluorescent molecules such as: fluorescein isothiocyanate (FITC), phycoerythrin (PE) or indocyanine (Cy5) .In the field of nuclear medicine, the ΓΞΗβ subunits may be conjugated with radioactive molecules such as: 123I, luIn, 188Re, 18F, 35S, "Tc.In a particular aspect, the ΓΞΗβ subunit may also be conjugated with nanoparticles of a different nature.The conjugation with nanoparticles may be through a suitable linker.Nanoparti cl esThe nanoparticles used in medicine as carriers (for example for drugs, radioisotopes, fluorescent molecules or enzymes) usually have a size of between 1 nm and 1 μπι.The nanoparticles may have smooth or uneven surface, may be solid, hollow, crossed by canaliculi or consisting of lenticular structures.Nanoparticles are particles made of inorganic or organic materials; inorganic-based ones may consist of Au, Ag, Si, Se, Cd or carbon compounds, such as graphene, while those of organic origin may consist, for example, of polymers of sugars or lipids (micelles, liposomes) or molecules such as poly ( lactic-co-glycolic) acid (PLGA) .The purpose of nanoparticles is to convey a large amount of molecules contained within them to the reference site .For the purposes of the present invention, the term "conjugated" means that the FSR subunit or an ΑΒΚβ subunit or, more specifically, an ΑΒΚβΙ subunit is suitably linked to a molecule with diagnostic or therapeutic activity.Such a bond, in particular, may be represented by a covalent chemical bond, directed or obtained by a suitable linker, or by a coordination bond.As for the origin of the FSR subunit, this can be obtained from the purification of human urine or using recombinant DNA techniques; it can also be obtained from commercial products such as Fertinex®, Metrodin HP®, Gonal-F® (Serono) , Follistim®, Puregon® (Merk Sharp & Dohme) .According to another aspect of the invention, the ΓΞΗβ subunit, in the conjugated form or in the non-con ugated form with molecules having therapeutic activity, is used in a method for the treatment of tumors in combination with a therapeutic agent (combo therapy) .The combination of the ΓΞΗβ subunit with the therapeutic agent is capable of providing a synergistic effect .Such a therapeutic agent may be selected from the group of molecules used in the treatment of the specific form of cancer.In a second object, the invention describes a biotechnological platform for the preparation of the β subunit of the human follicle stimulating hormone from plant cells and, more specifically, from Nicotiana benthamiana (ΑΒΚβΙ) .More generally, the biotechnological platform uses a process whereby the amino acid sequence of the ΓΞΗβ subunit is suitably modified so as to insert a signal peptide characteristic of the plant cells for the directing to the endoplasmic reticulum.The present invention therefore uses the KDEL sequence to modify the C-terminal region of the β subunit of the human follicle stimulating hormone (ΓΞΗβ), particularly in order to keep the protein in the endoplasmic reticulum.The resulting protein therefore undergoes a peculiar glycosylation process, which surprisingly leaves the processes which guide the protein folding unchanged.In particular, the ΑΒΚβΙ ligand of the present invention is glycosylated to the asparagine residues 13 and 30 of the mature protein.More in detail, the glycosylation sites include branched structures of mannose residues.Mannose residues are in a total number of about 45-75, preferably about 50-70 and even more preferably about 58-62, where they can be 60 or 61.Each glycosylation site includes two N-acetylglucosamine residues and a branched structure of mannose residues.In particular, each branched structure includes 29, 30 or 31 mannose residues.Each mannose residue may include phosphorylation, sulforylation or methylation.Moreover, the polysaccharide portions may be bound to molecules comprising phenol groups.Molecules comprising phenol groups are characteristic of plant cells.In particular, such phenol groups are typical of the plant cells of Nicotiana benthamiana .In a particular aspect, the object of the present invention is the ΕΞΗβ subunit (ΑΒΚβΙ) obtained with the process described herein.In particular, such a process comprises the modification at the C-terminal end with the KDEL sequence and at the N-terminal end with a 6 His-tags of the β subunit of the human follicle stimulating hormone (ΕΞΗβ) .The platform described by the present invention therefore uses the KDEL sequence at the C-terminal end and possibly also uses the of a His-tag at the N-terminal end of the sequence of the β subunit of the human follicle stimulating hormone (ΕΞΗβ) for the preparation of ligands of the human follicle stimulating hormone receptor (FHSR) .Therefore, according to a preferred aspect, the present invention describes a process for the preparation of a recombinant form of the β subunit of the follicle stimulating hormone (FSH) comprising the steps of:I) obtaining a suitable vector transformed with a plasmid containing the sequence corresponding to SEQ. ID. no. 3 ;II) transforming the Nicotiana benthamian acells with the vector of step I);III) selecting the transformed Nicotiana benthamiana cells ;IV) growing the stable Nicotiana benthamiana cells;V) preparing a cellular extract;VI) purifying an FSHR receptor ligand.In a preferred aspect, the vector of step I) is represented by Agrobacterium tumefaciens .In particular, in step II), the transformation is carried out for 48 hours co-culture in the dark at about 25°C and under constant stirring.Thereafter, the cells are selected.Preferably, in step III), a selection medium is used which comprises: MS supplemented with 0.9% w / v agar and antibiotics .In a preferred aspect, the following are used for this purpose: carbenicillin and kanamycin, more preferably 250 mg / L carbenicillin and 100 mg / L kanamycin.In a preferred aspect of the invention, in step V) , the Nicotiana benthamiana cells are cultured in suspension .In another preferred aspect, the culture provides for an initial inoculation of Nicotiana benthamiana cells equal to 10% of the final culture volume.The cellular culture is maintained in incubation in the MS medium (Murashige 1962) supplemented with sucrose, naphthalene-acetic acid (NAA) and kinetin for a period of 15 days at 24-27°C and maintaining an aeration of 50-100 mbar .In addition, sub-cultures are prepared every 7 days by transferring an aliquot of cell suspension in the fresh medium.The cells are incubated under stirring, in the dark and at a constant temperature of 25°C.According to the present invention, step V) includes the use of an extraction buffer containing: 50 mM Na2HP04, 150 mM NaCl, 20 mM citric acid, 40 mM ascorbic acid, 5 mM EDTA, 1 mM PMSF, 0.05% (v / v) Tween-20, pH 6.5 supplemented with 1% (w / v) XAD-4 and 1% (w / v) polyvinylpolypyrrolidone (PVPP) .Thereafter, ammonium sulfate is added to the extract up to obtaining a 70% saturation concentration, incubated at 4°C for 1 hour under constant stirring.The precipitate is then recovered by centrifugation and resuspended in an IMAC buffer.The preparation is centrifuged and filtered.The resulting solution is purified in a step VI) by passages on a column.In particular, the solution is loaded on an IMAC chromatography column.Preferably, an Ni Sepharose 6 FF column is used.Subsequently, the fractions of interest are combined and loaded on a desalting column.Preferably, a Sephadex G-25 Medium column is used.Subsequently, the fractions of interest are combined and loaded on a ion exchange chromatography column.Preferably, an SP Sepharose HP column is used.During the purification, the absorbance is monitored at 280 and 254 nm.As described above, the β subunit of the human follicle stimulating hormone (ΓΞΗβ) obtained according to the method described herein (ΑΒΚβΙ) and the medical use hereof in the treatment and / or diagnosis of tumors are further objects of the present invention.In particular, the present invention describes the use of the ΑΒΚβ subunit in the treatment and / or diagnosis of cancer.The term cancer refers to tumor and cancer, i.e. those tissues characterized by an abnormal growth caused by an uncontrolled cellular multiplication.In a preferred aspect, such a tumor or cancer is a primary or metastatic solid tumor.In detail, prostate, mammary gland, colon, pancreas, kidney, lung, liver, testis, ovary, brain and thyroid tumors and cancers are included; sarcomas are also included .According to an aspect of the invention, such a medical use may find application in the treatment of infant neuroblastoma.In particular, such a medical use is described in pediatric patients and, preferably, in patients up to 6 years of age.As described above, the ΑΒΚβΙ subunit is obtained by biotechnological route from the cultivation of plant cells of Nicotiana benthamiana in suspension.According to alternative aspects of the present invention, the ΑΒΚβ subunit may be obtained by biotechnological route in other cells, such as in mammalian, yeast, bacteria cells or other plant cells.In particular, among the plant cells, Daucus carota, Oryza sativa, Glycine max, Maize cells, etc., may be used.According to another aspect, pharmaceutical preparations for administering the FSR and ΑΒΚβ subunits and, more particularly, the ΑΒΚβΙ subunits, are described.More specifically, such preparations may include the ΓΞΗβ subunit or an ΑΒΚβ subunit or, more specifically, an ΑΒΚβΙ subunit and one or more pharmaceutically acceptable carriers and / or excipients.Such subunits, in preferred aspects of the invention, may be conjugated with suitable molecules having therapeutic or diagnostic activity, as described above with reference to the ΓΞΗβ subunit.According to another aspect of the invention, the ΑΒΚβΙ subunit, in the conjugated form or in the non-conjugated form with molecules having therapeutic activity, is also used in a method for the treatment of cancer in combination with a therapeutic agent (combo therapy) .The combination of the ΑΒΚβΙ subunit with the therapeutic agent is capable of providing a synergistic effect .Such a therapeutic agent may be selected from the group of molecules used in the treatment of the specific form of cancer.Therefore, the present invention provides diagnostic and therapeutic formulations comprising the ΑΒΚβΙ, ΓΞΗβ subunits described above or other ΑΒΚβ subunits (obtainable with the recombinant DNA technology applied to other cells) .More specifically, such preparations are formulated for intravenous administration.According to a further object, the present invention describes a method for the treatment and / or for the diagnosis of tumors comprising the use of the ΓΞΗβ, ΑΒΚβΙ subunit or other ΑΒΚβ subunits.In particular, such a method comprises the step of administering, to a patient in need thereof, a pharmaceutically effective amount of the ΓΞΗβ or ΑΒΚβ or ΑΒΚβΙ subunits possibly formulated in a suitable pharmaceutical preparation.For the present purposes, a patient is intended to be a subject suffering from a primary or metastatic solid tumor .In detail, prostate (in particular prostate adenocarcinoma) , mammary gland, colon, pancreas, kidney, lung, liver, testis, ovary, brain and thyroid tumors and cancers are included; sarcomas are also included.According to a particular aspect, such a method may find application in the treatment of infant neuroblastoma.In particular, such a medical use is described in pediatric patients and, preferably, in patients up to 6 years of age.Diagnostic method also refers to the ability of checking the tumor progression over time and / or its progression or regression during a therapeutic treatment.In other words, reference is made to a method for checking the progression of a tumor over time and / or its progression or regression during a therapeutic treatment comprising the steps of determining the extent of the tumor in a subject at different and subsequent times (such as a time to and a time ti) , wherein between said times (such as toand ti) a tumor treatment step may be conducted.The present invention provides a method for the in vivo inactivation of the FSHR receptor comprising the step of administering a pharmaceutically active amount of the FSYl or ΑΒΪβ or ΑΒΪβΙ subunit.Such a method may alternately be carried out in vitro in the laboratory for different purposes.According to a further aspect of the present invention, the use of the FSR or ΑΒΪβ or ΑΒΪβΙ subunit for inactivating the FSHR receptor is described.Such an inactivation, in particular, can be conducted in vivo or in vitro.Therefore in the present patent application, the following sequences are described:With reference to the sequence of the ΑΒΚβΙ subunit, all sequences which have a similarity with SEQ. ID. no. 2 such as to not modify the interaction with the FSHR receptor are intended to be comprised in the objects of the present invention.In particular, by "similarity" it is meant the percentage of amino acids occupying the same position which can be substituted with a different or structurally equivalent amino acid, where a similarity equal to 100% means that the two sequences are identical.The similarity may be determined by alignment, conducted in particular according to one or more known algorithms or programs, such as CLUSTALW or BLAST.In a preferred aspect of the invention, the percentage of similarity is in reference only to the sequence of the ΑΒΚβΙ subunit in common with the sequence of the ΓΞΗβ subunit .In another preferred aspect of the invention, the percentage of similarity is in reference only to the amino acids of the portions of the sequence of ΑΒΚβΙ which do not include the amino acids involved in the interaction with the receptor.The amino acids of the ΑΒΚβΙ involved in the interaction with the receptor correspond to amino acids 33-53 of the ΓΞΗβ sequence.For the purposes of the present invention, the similarity is greater than about 90%, preferably it is between about 90-99.9% and more preferably between about 95-97% .EXPERIMENTAL PART1. Production and purification of the ABR ligandThe protein sequence of human ΓΞΗβ (UniProt: P01225) was modified in silico as described in the following section relating to materials and methods. The gene sequence encoding for the novel protein, including the signal peptide region (ABRβl ligand) was optimized for the expression in plants (SEQ. ID. no. 3) .The nucleotide sequence was then inserted into the binary vector pABR expression cassette (Figure 1) and using Agrobacterium tumefaciens as plant cell transformation system, the stable clones of Nicotiana benthamiana expressing the highest level of the ABRβl ligand were obtained and selected.The ABRβl ligand was purified from plant cells cultured in suspension using sequential chromatographies.2. Chemical characterization of the ABRβl ligandThe ABRβl ligand obtained after optimizing the purification process was analyzed using SDS-PAGE electrophoresis .The immunoblotting analysis with human ΓΞΗβ specific antibody and polyacrylamide gels subjected to staining with Coomassie Brilliant Blue or with the more sensitive silver staining show that the ΑΒΚβΙ ligand achieves a purity level of 95-98%. The analysis reveals the existence of two reactive species to the FSR antibody.Figure 2 shows the results of the electrophoretic analysis of purified ΑΒΚβΙ. 0.1 μg of purified ΑΒΚβΙ are analyzed in SDS-PAGE. MW molecular weight marker; SS, silver staining; WB, immunoblotting using human FSIH^ specific antibody. The forms at 25 and 37 kDa detected by silver staining are reactive to the human FSIH^ specific antibody. The two species of apparent molecular weight of 25 kDa and 37 kDa are the result of the different protein glycosylation pattern. The treatment of the sample with a glycosylase (PNGase F) produces the disappearance of the two high molecular weight species into a single form of apparent molecular weight of 14 kDa.Figure 3 shows the SDS-PAGE analysis results after deglycosylation of purified ΑΒΚβΙ. 0.1 μg of purified ΑΒΚβΙ were subjected to deglycosylation protocol and analyzed in SDS-PAGE and subsequent silver staining. To the left, molecular weight marker; 1, ΑΒΚβΙ ligand purified and not deglycosylated; 2, ΑΒΚβΙ ligand purified and subjected to deglycosylation. The glycosylated forms at 25 and 37 kDa disappear after deglycosylation and the generation of a non-deglycosylated form having apparent weight of 14 kDa is observed.
Claims
CLAIMS :
1. A ligand of the human follicle stimulating hormone receptor (FSHR) characterized by the sequence corresponding to SEQ. ID. no. 2 or a sequence having a similarity of at least about 90% with it, preferably between about 90-99%.9 and more preferably between about 95-97% .
2. A ligand of the human follicle stimulating hormone receptor (FSHR) characterized by being encoded by the sequence corresponding to SEQ. ID. no. 3.
3. A ligand of the human follicle stimulating hormone receptor (FSHR) according to claim 1 or 2, characterized by comprising glycosylation sites at the arginine residues N13 and N30 of the mature protein, said glycosylation sites comprising each two N-acetylglucosamine residues and mannose residues.
4. A ligand of the human follicle stimulating hormone receptor according to any one of the preceding claims for medical use.
5. A ligand of the human follicle stimulating hormone receptor (FSHR) according to the preceding claim for medical use in the treatment and / or diagnosis of tumors.
6. A ligand of the human follicle stimulating hormone receptor (FSHR) according to the preceding claim 4 or 5 for use in the treatment and / or diagnosis of tumors, wherein said tumors are primary or metastatic solid tumors .
7. A ligand of the human follicle stimulating hormone receptor (FSHR) according to any one of the preceding claims 4 to 6 for use in the treatment of tumors, wherein said tumors comprise: prostate cancer and in particular prostate adenocarcinoma, mammary gland, colon, pancreas, kidney, lung, liver, testis, ovary, brain and thyroid cancer, sarcomas.
8. A ligand of the human follicle stimulating hormone receptor (FSHR) according to any one of the preceding claims 4 to 7 for use in the treatment of tumors, wherein said ligand is conjugated to a molecule having anti-tumor activity selected from the group comprising:- the class of cytotoxic agents, where such compounds are preferably selected from the group comprising: pyrimidine antagonists, such as capecitabine, enzyme inhibitors, such as the camptothecins family, for example irinotecan;- the class of alkylating agents, where such compounds are preferably selected from the group comprising: the metal salts family, such as cisplatin, DNA intercalators , such as doxorubicin, the anthracycline family;- the class of protein synthesis modulators, where such compounds are preferably selected from the group comprising: the proteasome inhibitors family, such as bortezomib, the mTOR inhibitors family, such as temsirolimus ;the class of mitotic inhibitors, where such compounds are preferably selected from the group comprising: the ansamitocin family, such as maytansine, the microtubule polymerization inhibitors family, such as auristatin E;- the class of β-emitting radioisotopes, where such compounds are preferably selected from the group comprising: 131I, 169Er, 177Lu, 186Re, 153Sm, 89Sr and 90Y.
9. A ligand of the human follicle stimulating hormone receptor (FSHR) according to any one of the preceding claims 4 to 8, in conjugated or non-con ugated form, for use in the treatment of tumors in combination with one or more agents with anti-tumor activity.
10. A ligand of the human follicle stimulating hormone receptor (FSHR) according to any one of the preceding claims 4 to 7 for use in the diagnosis of tumors and / or for in vitro analysis, wherein said ligand is conjugated to:fluorescent molecules selected from the group comprising: fluorescein isothiocyanate (FITC), phycoerythrin (PE) or indocyanine (Cy5) ; orradioactive molecules selected from the group comprising: 123I, min, 188Re, 18F, 35S, "Tc;- nanoparticles .
11. A ligand of the human follicle stimulating hormone receptor (FSHR) according to claim 1 or 2 or 3, wherein said ligand is conjugated to a molecule having anti-tumor activity selected from the group comprising:
12. A ligand of the human follicle stimulating hormone receptor (FSHR) according to claim 1 or 2 or 3, wherein said ligand is conjugated to a molecule having diagnostic activity selected from the group comprising:
13. A pharmaceutical preparation comprising the ligand of the human follicle stimulating hormone receptor (FSHR) according to claim 1 or 2 or 3 and one or more pharmaceutically acceptable carriers and / or excipients.
14. A pharmaceutical preparation comprising the ligand of the human follicle stimulating hormone receptor (FSHR) according to claim 11 or 12 and one or more pharmaceutically acceptable carriers and / or excipients.
15. A pharmaceutical preparation according to claim 13 or 14 for intravenous administration.
16. Use the ligand of the human follicle stimulating hormone receptor (FSHR) according to claim 1 or 2 or 3 for the in vitro inactivation of said receptor.
17. A method for the preparation of the ligand of the human follicle stimulating hormone receptor (FSHR) according to claim 1 or 2 or 3, comprising the step of modifying the C-terminal region of the sequence of the β subunit of the human follicle stimulating hormone (ΓΞΗβ) through the introduction of the amino acid sequence KDEL.
18. A method for the preparation of the ligand of the human follicle stimulating hormone receptor (FSHR) according to the preceding claim, comprising the further step of introducing a His-tag at the N-terminal end of the sequence of the β subunit of the human follicle stimulating hormone (ΓΞΗβ) .
19. A ligand of the human follicle stimulating hormone receptor (FSHR) characterized by being represented by the β subunit of the human follicle stimulating hormone (ΕΞΗβ) for medical use.
20. A ligand of the human follicle stimulating hormone receptor (FSHR) according to the preceding claim for medical use in the treatment and / or diagnosis of tumors.
21. A ligand of the human follicle stimulating hormone receptor (FSHR) according to the preceding claim 19 or 20 for use in the treatment and / or diagnosis of tumors, wherein said tumors are primary or metastatic solid tumors .
22. A ligand of the human follicle stimulating hormone receptor (FSHR) according to the preceding claim 20 or 21, wherein said tumors comprise: prostate cancer and in particular prostate adenocarcinoma, mammary gland, colon, pancreas, kidney, lung, liver, testis, ovary, brain and thyroid cancer, sarcomas.
23. A ligand of the human follicle stimulating hormone receptor (FSHR) according to any one of the preceding claims 4 to 22 for use in the treatment of tumors, wherein said ligand is conjugated to a molecule having anti-tumor activity selected from the group comprising:
24. A ligand of the human follicle stimulating hormone receptor (FSHR) according to any one of the preceding claims 19 to 23, in conjugated or non-con ugated form, for use in the treatment of tumors in combination with one or more agents with anti-tumor activity.
25. A ligand of the human follicle stimulating hormone receptor (FSHR) according to any one of the preceding claims 19 to 24 for use in the diagnosis of tumors and / or for conducting in vitro analyses, wherein said subunit is conjugated to:radioactive molecules selected from the group comprising: 123I, min, 188Re, 18F, 35S, "Tc; or26. A ligand of the human follicle stimulating hormone receptor (FSHR) according to any one of the preceding claims 19 to 25 conjugated to a molecule having anti- tumor activity selected from the group comprising:
27. A ligand of the human follicle stimulating hormone receptor (FSHR) according to any one of the preceding claims 19 to 26 conjugated to a molecule having diagnostic activity selected from the group comprising:
28. A ligand of the human follicle stimulating hormone receptor (FSHR) according to any one of the preceding claims 19 to 27, wherein said subunit is of human origin or is obtained by recombinant DNA techniques.
29. A pharmaceutical preparation comprising the ligand of the human follicle stimulating hormone receptor (FSHR) according to any one of the preceding claims 19 to 28 and one or more pharmaceutically acceptable carriers and / or excipients .
30. A pharmaceutical preparation according to claim 29 for intravenous administration.
31. Use of the ΡΞΗβ subunit of the human follicle stimulating hormone (FSHR) for the in vitro inactivation of the FSHR receptor.
32. A ligand of the follicle stimulating hormone (FSH) for medical use in the treatment and / or diagnosis of neuroblastoma .
33. A ligand of the follicle stimulating hormone (FSH) according to the preceding claim, characterized in that it comprises:the sequence of the β subunit of the follicle stimulating hormone (ΓΞΗβ); or- the amino acid sequence corresponding to SEQ. ID. no. 2.
34. A ligand of the follicle stimulating hormone (FSH) according to the preceding claim, wherein said amino acid sequence is characterized by comprising glycosylation sites at the arginine residues N13 and N30 of the mature protein, said glycosylation sites comprising each two N-acetylglucosamine residues and mannose residues.
35. A ligand according to any one of the preceding claims 32 to 34, wherein said tumor is in a pediatric patient, and preferably in a patient up to 6 years of age.
36. A ligand of the follicle stimulating hormone (FSH) according to any one of the preceding claims 32 to 35 for medical use in the treatment of neuroblastoma, wherein said ligand is conjugated to a molecule having anti-tumor activity selected from the group comprising:
37. A ligand of the follicle stimulating hormone (FSH) according to any one of the preceding claims 32 to 36 for medical use in the treatment of neuroblastoma, wherein said ligand, in the conjugated or non-con ugated form, is used in combination with one or agents having anti-tumor activity .
38. A ligand of the follicle stimulating hormone (FSH) according to any one of the preceding claims 32 to 37 for use in the diagnosis of neuroblastoma, wherein said subunit is conjugated to:
39. A pharmaceutical preparation comprising the ligand of the follicle stimulating hormone (FSH) according to any one of the preceding claims 32 to 38, for medical use in the treatment and / or diagnosis of neuroblastoma and one or more pharmaceutically acceptable carriers and / or excipients .
40. A pharmaceutical preparation according to the preceding claim for intravenous administration.
41. A process for preparing a ligand of the follicle stimulating hormone (FSH) receptor represented by the β subunit of the follicle stimulating hormone (FSH), comprising the steps of:I) obtaining a suitable vector transformed with a plasmid containing the sequence corresponding to SEQ. ID. no. 3 ;II) transforming the Nicotiana benthamiana cells with the vector of step I);III) selecting the Nicotiana benthamiana cells;IV) growing the stable Nicotiana benthamiana cells;V) preparing a cellular extract;VI) purifying an FSHR receptor ligand.
42. A process according to the preceding claim, wherein the vector of step I) is represented by Agrobacterium tumefaciens .
43. A process according to claim 41 or 42, wherein in step II), the transformation is carried out for 48 hours co-culture in the dark at about 25 °C and under constant stirring .
44. A process according to any one of the preceding claims 41 to 43, a selection medium is used in step III) which comprises: MS supplemented with 0.9% w / v agar and antibiotics .
45. A process according to any one of the preceding claims 41 to 44, wherein carbenicillin and kanamycin are used in step III) .
46. A process according to any one of the preceding claims 41 to 45, wherein in step V) , the Nicotiana benthamiana cells are cultured in suspension.
47. A process according to any one of the preceding claims 41 to 46, wherein in step V), the Nicotiana benthamiana cells are maintained in incubation in the MS medium (Murashige 1962) supplemented with sucrose, naphthalene- acetic acid (NAA) and kinetin for a period of 15 days at 24-27°C and maintaining an aeration of 50-100 mbar.
48. A process according to any one of the preceding claims 41 to 47, wherein an extraction buffer is used in step V) which comprises: 50 mM Na2HPC>4, 150 mM NaCl, 20 mM citric acid, 40 mM ascorbic acid, 5 mM EDTA, 1 mM PMSF, 0.05% (v / v) Tween-20, pH 6.5 supplemented with 1% (w / v) XAD-4 and 1% (w / v) polyvinylpolypyrrolidone (PVPP) .
49. A process according to any one of the preceding claims 41 to 48, wherein step VI) is carried out using in a sequence: a chromatography column IMAC, a desaling column and a ion exchange chromatography column.
50. A ligand of the follicle stimulating hormone (FSH) receptor represented by subnit β of the follicle stimulating hormone (FSH) obtainable by the process of any one of claims 41 to 49.
